OncoTherapy Science Past Earnings Performance
Past criteria checks 0/6
OncoTherapy Science has been growing earnings at an average annual rate of 14.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 20.5% per year.
Key information
14.9%
Earnings growth rate
21.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 20.5% |
| Return on equity | -112.4% |
| Net Margin | -234.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How OncoTherapy Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 479 | -1,123 | 265 | 0 |
| 30 Jun 24 | 562 | -1,190 | 260 | 0 |
| 31 Mar 24 | 610 | -1,288 | 261 | 0 |
| 31 Dec 23 | 901 | -1,192 | 255 | 0 |
| 30 Sep 23 | 976 | -1,215 | 270 | 0 |
| 30 Jun 23 | 897 | -1,241 | 277 | 0 |
| 31 Mar 23 | 1,134 | -1,118 | 287 | 0 |
| 31 Dec 22 | 1,517 | -1,345 | 293 | 0 |
| 30 Sep 22 | 1,427 | -1,955 | 289 | 0 |
| 30 Jun 22 | 1,445 | -2,314 | 294 | 0 |
| 31 Mar 22 | 1,153 | -2,571 | 294 | 0 |
| 31 Dec 21 | 507 | -2,518 | 391 | 0 |
| 30 Sep 21 | 472 | -2,034 | 358 | 0 |
| 30 Jun 21 | 384 | -1,777 | 327 | 0 |
| 31 Mar 21 | 332 | -1,561 | 281 | 0 |
| 31 Dec 20 | 315 | -1,645 | 182 | 0 |
| 30 Sep 20 | 312 | -1,738 | 205 | 0 |
| 30 Jun 20 | 302 | -1,911 | 240 | 0 |
| 31 Mar 20 | 316 | -2,238 | 271 | 0 |
| 31 Dec 19 | 194 | -2,815 | 381 | 0 |
| 30 Sep 19 | 360 | -2,648 | 355 | 0 |
| 30 Jun 19 | 322 | -2,932 | 334 | 0 |
| 31 Mar 19 | 280 | -2,934 | 296 | 0 |
| 31 Dec 18 | 255 | -2,599 | 268 | 0 |
| 30 Sep 18 | 34 | -3,026 | 266 | 0 |
| 30 Jun 18 | 24 | -2,930 | 249 | 0 |
| 31 Mar 18 | 211 | -2,851 | 251 | 0 |
| 31 Dec 17 | 255 | -2,949 | 192 | 0 |
| 30 Sep 17 | 453 | -2,872 | 214 | 0 |
| 30 Jun 17 | 486 | -2,806 | 234 | 0 |
| 31 Mar 17 | 286 | -3,002 | 262 | 0 |
| 31 Dec 16 | 290 | -2,864 | 278 | 0 |
| 30 Sep 16 | 92 | -2,951 | 285 | 0 |
| 30 Jun 16 | 60 | -3,012 | 295 | 0 |
| 31 Mar 16 | 266 | -2,788 | 296 | 0 |
| 31 Dec 15 | 581 | -2,464 | 319 | 0 |
| 30 Sep 15 | 626 | -1,921 | 302 | 0 |
| 30 Jun 15 | 671 | -1,706 | 296 | 0 |
| 31 Mar 15 | 769 | -1,334 | 282 | 0 |
| 31 Dec 14 | 651 | -1,769 | 225 | 0 |
| 30 Sep 14 | 1,035 | -2,409 | 229 | 0 |
| 30 Jun 14 | 1,110 | -2,793 | 250 | 0 |
| 31 Mar 14 | 1,017 | -3,676 | 235 | 0 |
| 31 Dec 13 | 2,303 | -2,425 | 293 | 0 |
Quality Earnings: 30O is currently unprofitable.
Growing Profit Margin: 30O is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 30O is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.
Accelerating Growth: Unable to compare 30O's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 30O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 30O has a negative Return on Equity (-112.41%), as it is currently unprofitable.